Malignancy-associated multicentric reticulohistiocytosis

Boutros N El-Haddad, Dalia Hammoud, Timothy Shaver, Shadi Shahouri

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Multicentric reticulohistiocytosis (MR) is a rare systemic disorder of unknown etiology. Up to 25% of patients with MR have associated malignancies. We are reporting a case of a patient with MR who initially had an excellent clinical response to oral methotrexate and prednisone. Subsequent attempts of prednisone taper failed because of disease flare-up. Workup for associated malignancy revealed localized squamous cell carcinoma of the lung. The tumor was resected; methotrexate and prednisone were tapered and discontinued with complete remission of MR. A review of literature and the new advances and treatment modalities for MR is provided.

Original languageEnglish (US)
Pages (from-to)1235-1238
Number of pages4
JournalRheumatology International
Volume31
Issue number9
DOIs
StatePublished - Sep 1 2011

Keywords

  • Histiocytes
  • Malignancy
  • Multicentric reticulohistiocytosis
  • Multinucleated giant cells
  • Paraneoplastic

Fingerprint Dive into the research topics of 'Malignancy-associated multicentric reticulohistiocytosis'. Together they form a unique fingerprint.

  • Cite this

    El-Haddad, B. N., Hammoud, D., Shaver, T., & Shahouri, S. (2011). Malignancy-associated multicentric reticulohistiocytosis. Rheumatology International, 31(9), 1235-1238. https://doi.org/10.1007/s00296-009-1287-7